JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kristiansen, K.
Right arrow Articles by Roth, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kristiansen, K.
Right arrow Articles by Roth, B. L.

Vol. 293, Issue 3, 735-746, June 2000

A Highly Conserved Aspartic Acid (Asp-155) Anchors the Terminal Amine Moiety of Tryptamines and Is Involved in Membrane Targeting of the 5-HT2A Serotonin Receptor But Does Not Participate in Activation via a "Salt-Bridge Disruption" Mechanism1

Kurt Kristiansen2 , Wesley K. Kroeze, David L. Willins, Edward I. Gelber, Jason E. Savage, Richard A. Glennon and Bryan L. Roth

Departments of Biochemistry (K.K., W.K.K., E.I.G., J.E.S., B.L.R.), Psychiatry (D.L.W., B.L.R.), and Neurosciences (B.L.R.), Case Western Reserve University Medical School, Cleveland, Ohio; and Department of Medicinal Chemistry, Medical College of Virginia, Richmond, Virginia (R.A.G.)

Discovering the molecular and atomic mechanism(s) by which G-protein-coupled receptors (GPCRs) are activated by agonists remains an elusive goal. Recently, studies examining two representative GPCRs (rhodopsin and alpha 1b-adrenergic receptors) have suggested that the disruption of a putative "salt-bridge" between highly conserved residues in transmembrane (TM) helix III, involving aspartate or glutamate, and helix VII, involving a basic residue, results in receptor activation. We have tested whether this is a general mechanism for GPCR activation by constructing a model of the 5-hydroxytryptamine (5-HT)2A receptor and characterizing several mutations at the homologous residues (Asp-155 and Asn-363) of the 5-HT2A serotonin receptor. All of the mutants (D155A, D155N, D155E, D155Q, and S363A) resulted in receptors with reduced basal activity; in no case was evidence for constitutive activity revealed. Structure-function studies with tryptamine analogs and various Asp-155 mutants demonstrated that Asp-155 interacts with the terminal, and not indole, amine moiety of 5-HT2A agonists. Interestingly, the D155E mutation interfered with the membrane targeting of the 5-HT2A receptor, and an inverse relationship was discovered when comparing receptor activation and targeting for a series of Asp-155 mutants. This represents the first known instance in which a charged residue located in a putative TM helix alters the membrane targeting of a GPCR. Thus, for 5-HT2A receptors, the TMIII aspartic acid (Asp-155) is involved in anchoring the terminal amine moiety of indole agonists and in membrane targeting and not in receptor activation by salt-bridge disruption.

1 This study was supported in part by National Institutes of Health Grants RO1MH57635, Research Scientist Development Award KO2MH01366, a gift from the Heffter Research Foundation, and a National Alliance for Research on Schizophrenia and Depression Independent Investigator Award (to B.L.R.). D.L.W. was supported in part by a National Alliance for Research on Schizophrenia and Depression Young Investigator Award.

2 Current address: Institute of Molecular Pharmacology, Molecular Modeling Group, Alfred Kowalke Str. 4, D-10315 Berlin, Germany.

0022-3565/00/2933-0735$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Exp. Biol.Home page
N. Spitzer, D. H. Edwards, and D. J. Baro
Conservation of structure, signaling and pharmacology between two serotonin receptor subtypes from decapod crustaceans, Panulirus interruptus and Procambarus clarkii
J. Exp. Biol., January 1, 2008; 211(1): 92 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Braden and D. E. Nichols
Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor
Mol. Pharmacol., November 1, 2007; 72(5): 1200 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. R. Braden, J. C. Parrish, J. C. Naylor, and D. E. Nichols
Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists
Mol. Pharmacol., December 1, 2006; 70(6): 1956 - 1964.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
V. Setola, M. Dukat, R. A. Glennon, and B. L. Roth
Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor
Mol. Pharmacol., July 1, 2005; 68(1): 20 - 33.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. C. Clark, T. E. Dever, J. J. Dever, P. Xu, V. Rehder, M. A. Sosa, and D. J. Baro
Arthropod 5-HT2 Receptors: A Neurohormonal Receptor in Decapod Crustaceans That Displays Agonist Independent Activity Resulting from an Evolutionary Alteration to the DRY Motif
J. Neurosci., March 31, 2004; 24(13): 3421 - 3435.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. D. Hirst, B. Abrahamsen, F. E. Blaney, A. R. Calver, L. Aloj, G. W. Price, and A. D. Medhurst
Differences in the Central Nervous System Distribution and Pharmacology of the Mouse 5-Hydroxytryptamine-6 Receptor Compared with Rat and Human Receptors Investigated by Radioligand Binding, Site-Directed Mutagenesis, and Molecular Modeling
Mol. Pharmacol., December 1, 2003; 64(6): 1295 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. J. Ebersole, I. Visiers, H. Weinstein, and S. C. Sealfon
Molecular Basis of Partial Agonism: Orientation of Indoleamine Ligands in the Binding Pocket of the Human Serotonin 5-HT2A Receptor Determines Relative Efficacy
Mol. Pharmacol., January 1, 2003; 63(1): 36 - 43.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. A. Shapiro, K. Kristiansen, D. M. Weiner, W. K. Kroeze, and B. L. Roth
Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6
J. Biol. Chem., March 22, 2002; 277(13): 11441 - 11449.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Rauser, J. E. Savage, H. Y. Meltzer, and B. L. Roth
Inverse Agonist Actions of Typical and Atypical Antipsychotic Drugs at the Human 5-Hydroxytryptamine2C Receptor
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 83 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Nguyen, D. A. Shapiro, S. R. George, V. Setola, D. K. Lee, R. Cheng, L. Rauser, S. P. Lee, K. R. Lynch, B. L. Roth, et al.
Discovery of a Novel Member of the Histamine Receptor Family
Mol. Pharmacol., March 1, 2001; 59(3): 427 - 433.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
D. A. Shapiro, K. Kristiansen, W. K. Kroeze, and B. L. Roth
Differential Modes of Agonist Binding to 5-Hydroxytryptamine2A Serotonin Receptors Revealed by Mutation and Molecular Modeling of Conserved Residues in Transmembrane Region 5
Mol. Pharmacol., November 1, 2000; 58(5): 877 - 886.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.